Pharma-backed TransCelerate makes progress on clinical trial efficiency
This article was originally published in SRA
Executive Summary
TransCelerate BioPharma, the non-profit organization founded by 10 big pharma companies to quickly address issues that hamper clinical trial efficiency, has taken swift action on all five of the objectives the group outlined in 2012 when it was first established. In addition, the group has adopted a list of five new priorities.
You may also be interested in...
Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock
Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.